Tags

Type your tag names separated by a space and hit enter

Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Haematologica. 2006 Jun; 91(6 Suppl):ELT04.H

Abstract

An expert group of the International Committee on Oral Chelators (ICOC) has recommended a universally effective chelation combination protocol of oral deferiprone (L1) during the day (80-110 mg/kg /day) and subcutaneous deferoxamine (40-60 mg/kg) of a minimum of three nights per week for the rapid, safe and effective depletion of excess body iron in transfused iron loaded patients. Following the clearance of excess cardiac and liver iron load, deferiprone (L1) monotherapy at doses exceeding 80 mg/kg/day has been recommended for preventing the re-accumulation of excess iron in the heart and other organs. New chelators such as deferasirox may also be used in combinations with deferiprone (L1) and deferoxamine, especially in patients not tolerating the deferiprone (L1) / deferoxamine combination.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Letter

Language

eng

PubMed ID

16785141

Citation

Kontoghiorghes, George J., and Annita Kolnagou. "Effective New Treatments of Iron Overload in Thalassaemia Using the ICOC Combination Therapy Protocol of Deferiprone (L1) and Deferoxamine and of New Chelating Drugs." Haematologica, vol. 91, no. 6 Suppl, 2006, pp. ELT04.
Kontoghiorghes GJ, Kolnagou A. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs. Haematologica. 2006;91(6 Suppl):ELT04.
Kontoghiorghes, G. J., & Kolnagou, A. (2006). Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs. Haematologica, 91(6 Suppl), ELT04.
Kontoghiorghes GJ, Kolnagou A. Effective New Treatments of Iron Overload in Thalassaemia Using the ICOC Combination Therapy Protocol of Deferiprone (L1) and Deferoxamine and of New Chelating Drugs. Haematologica. 2006;91(6 Suppl):ELT04. PubMed PMID: 16785141.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs. AU - Kontoghiorghes,George J, AU - Kolnagou,Annita, PY - 2006/6/21/pubmed PY - 2006/10/6/medline PY - 2006/6/21/entrez SP - ELT04 EP - ELT04 JF - Haematologica JO - Haematologica VL - 91 IS - 6 Suppl N2 - An expert group of the International Committee on Oral Chelators (ICOC) has recommended a universally effective chelation combination protocol of oral deferiprone (L1) during the day (80-110 mg/kg /day) and subcutaneous deferoxamine (40-60 mg/kg) of a minimum of three nights per week for the rapid, safe and effective depletion of excess body iron in transfused iron loaded patients. Following the clearance of excess cardiac and liver iron load, deferiprone (L1) monotherapy at doses exceeding 80 mg/kg/day has been recommended for preventing the re-accumulation of excess iron in the heart and other organs. New chelators such as deferasirox may also be used in combinations with deferiprone (L1) and deferoxamine, especially in patients not tolerating the deferiprone (L1) / deferoxamine combination. SN - 1592-8721 UR - https://www.unboundmedicine.com/medline/citation/16785141/Effective_new_treatments_of_iron_overload_in_thalassaemia_using_the_ICOC_combination_therapy_protocol_of_deferiprone__L1__and_deferoxamine_and_of_new_chelating_drugs_ L2 - http://www.diseaseinfosearch.org/result/3874 DB - PRIME DP - Unbound Medicine ER -